Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company’s products are based on the EVade™ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.

The EVade™ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company has advanced lead candidate QBI-139 into a Phase I human clinical trial at the University of Wisconsin Comprehensive Cancer Center.Second generation products are under development and pre-clinical work is ongoing.

Research Grants show all

NIH7

Publications show all

Quintessence Biosciences has published 4 articles.

Patents show all

16Issued15Applications

Clinical Trials show all

1Phase 1

SEC Filings show all

D2

Contact Information

505 South Rosa Road
Madison, WI 53719
United States

6084412952

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $1,486,00011-502012-06-26Closed

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2012-06-26$1,486,000Venture

    SEC Form D Funding Events

    DateOfferedSoldType
    2012-06-26$1,486,000$1,486,000Equity
    2008-02-29UnknownUnknownOther (Paper Filing)

    Key Executives

    • Ronald T. Raines
      Director
    • Laura L. Kiessling
      Director
    • Ralph Kauten
      Executive Officer, Director
    • Laura E. Strong
      Executive Officer